Shenzhen Edge Medical Co., Ltd. (Edge Medical) disclosed that on 7 October 2026 it repurchased 57,700 H-shares on the Hong Kong Stock Exchange, paying an aggregate HKD 1.90 million at prices ranging between HKD 32.80 and HKD 33.00 per share. The volume-weighted average price was HKD 32.97.

Following the transaction, issued shares (excluding treasury stock) declined 0.0177 % to 325.44 million, while treasury shares increased to 2.32 million. The company’s total share count remained unchanged at 327.76 million.

The repurchase formed part of the mandate approved by shareholders on 25 June 2026, which authorises the buyback of up to 32.61 million shares. Cumulative purchases under this mandate now stand at 704,900 shares, equivalent to 0.22 % of the company’s issued shares as at the mandate date.

All repurchased shares have been retained as treasury stock; none have been cancelled. Under Hong Kong listing rules, Edge Medical is restricted from issuing, selling, or transferring any shares for 30 days following the latest buyback, setting a moratorium period until 6 November 2026.